Latest news with #NektarTherapeutics
Business Insider
2 days ago
- Business
- Business Insider
Upcoming Stock Splits This Week (June 9 to June 13)
These are the upcoming stock splits for the week of June 9 to June 13, based on TipRanks' Stock Splits Calendar. A stock split is a corporate maneuver that increases the number of shares outstanding by issuing more shares to existing holders, all while keeping the company's total market value unchanged. This lowers the price per share, often making the stock more affordable and potentially more appealing to retail investors. Confident Investing Starts Here: In contrast, a reverse stock split reduces the number of shares by consolidating them, which raises the price per share without affecting the company's valuation. Companies typically turn to this strategy to meet stock exchange requirements – like Nasdaq's minimum price threshold – and avoid delisting. Whether intended to boost investor interest or maintain compliance with exchange rules, these adjustments often serve as key signals for traders tracking a company's strategic direction. Let's take a look at the upcoming stock splits for the week. Nektar Therapeutics (NKTR) – Nektar Therapeutics is a biopharmaceutical company developing novel drug candidates. Following stockholder approval on May 23, the company formalized a 1-for-15 reverse stock split. The split takes effect on June 8, with trading on a split‑adjusted basis beginning June 9. Fangdd Network Group (DUO) – China-based Fangdd is a technology-driven real estate platform. The company confirmed a 16-for-1 reverse share consolidation, effective June 9, aimed at boosting its share price and maintaining compliance with listing standards. Bone Biologics (BBLG) – Bone Biologics develops orthobiologic products for spinal fusion procedures. After gaining shareholder approval on May 30, the company filed for a 1-for-6 reverse stock split, which takes effect on June 10. The goal is to elevate its share price back into compliance with Nasdaq's minimum pricing rules and enhance its appeal to institutional investors. Cero Therapeutics Holdings (CERO) – Cero Therapeutics is a biotech firm developing engineered T-cell immunotherapies for cancer. Following shareholder approval in November and board action on December 25, it enacted a 1-for-100 reverse stock split effective on January 8, consolidating every 100 shares into one. The move aimed to boost the stock above $1.00 and secure compliance with Nasdaq's listing standards. Inuvo, Inc. (INUV) – Inuvo specializes in AI-powered marketing technologies and is gearing up for a 1-for-10 reverse stock split on June 10. The move is designed to lift its share price, restore Nasdaq compliance, and strengthen its financial foundation for future growth. O'Reilly Automotive (ORLY) – O'Reilly Automotive is a specialty retailer of automotive aftermarket parts and accessories. On March 13, the company declared a 15-for-1 forward stock split, with the distribution of additional shares set for June 9 and split-adjusted trading beginning June 10. SaverOne 2014 (SVRE) – Israel-based SaverOne develops driver safety systems that block mobile-device distractions in vehicles. The company executed a 1-for-3 reverse ADS split, effective June 11, adjusting its American Depositary Share ratio to strengthen its Nasdaq standing and enhance market appeal. China Natural Resources, Inc. (CHNR) – China Natural Resources is focused on mining exploration in Inner Mongolia and is working toward picking up Zimbabwe's Williams Minerals lithium mine for up to $1.75 billion. The company executed an 8-for-1 reverse stock split effective June 12 to meet Nasdaq's $1 minimum bid price requirement, converting every eight shares into one to boost its per-share value and comply with listing rules
Yahoo
11-05-2025
- Business
- Yahoo
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations
Revenue: US$10.5m (down 52% from 1Q 2024). Net loss: US$50.9m (loss widened by 38% from 1Q 2024). US$0.24 loss per share (further deteriorated from US$0.19 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Nektar Therapeutics. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 44%. Looking ahead, revenue is expected to decline by 5.1% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.3%. Performance of the American Pharmaceuticals industry. The company's shares are down 22% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Nektar Therapeutics (at least 1 which is significant), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Washington Post
08-05-2025
- Business
- Washington Post
Nektar: Q1 Earnings Snapshot
SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $50.9 million in its first quarter. On a per-share basis, the San Francisco-based company said it had a loss of 24 cents. Losses, adjusted for non-recurring costs, came to 22 cents per share. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.
Yahoo
22-03-2025
- Business
- Yahoo
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil
We recently published a list of . In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%. Markets continue to scare retail investors as stock after stock struggles to deal with the aftermath of Donald Trump's unpredictable and aggressive policies. While it is advisable to stay out of the market till the dust settles, one also can't deny that it is times like these that bring opportunities. We decided to come up with a list of stocks that are expected to go up even in the existing gloomy environment. To come up with the list of 10 stocks that Wall Street is bullish on, we looked at stocks that were recently upgraded by analysts and have performed well in the last 5 days of trading. A scientist in lab coat testing a new biopharmaceutical drug on a microscope. Nektar Therapeutics (NASDAQ:NKTR) operates as a biopharmaceutical company that discovers and develops therapies to treat autoimmune disorders. Its products include NKTR-358, PEG-CSF1, and others. The company's stock price gained 6% in the previous year despite a downturn in the second half of the year. Based on 9 different analyst ratings, NKTR has the highest target price of $7 which means it has the potential to grow more than six times higher from the current levels if the bull thesis holds true. The stock is currently trading at $0.91 which is 9.97% below the lowest Wall Street price target of $1. Nektar Therapeutics (NASDAQ:NKTR) was recently upgraded by Oppenheimer from Perform to Outperform with a price target of $6. According to the analysts, the company's stock valuation was attractive prior to the mid-stage trial results for its eczema therapy Rezpegaldesleukin. Analyst Jay Olson emphasized that Rezpeg's distinctive profile places it in a strong position to grow in an expanding market and could offer significant benefits for eczema patients. Despite risks, investors could make 6x their money in this stock. Overall, NKTR ranks 6th on our list of stocks that Wall Street is calling bullish amid market turmoil. While we acknowledge the potential of NKTR as a leading investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as NKTR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Associated Press
20-03-2025
- Business
- Associated Press
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link here The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow Nektar on LinkedIn. Contact: For Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC [email protected] 212-915-2577 Ahu Demir, Ph.D. LifeSci Advisors, LLC 212-915-3820 For Media: Madelin Hawtin LifeSci Communications 603-714-2638
